BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25431591)

  • 1. Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype.
    Takano S; Akutsu H; Hara T; Yamamoto T; Matsumura A
    Int J Endocrinol; 2014; 2014():989574. PubMed ID: 25431591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas.
    Viacava P; Gasperi M; Acerbi G; Manetti L; Cecconi E; Bonadio AG; Naccarato AG; Acerbi F; Parenti G; Lupi I; Genovesi M; Martino E
    J Endocrinol Invest; 2003 Jan; 26(1):23-8. PubMed ID: 12602530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
    Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
    Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF and CD31 association in pituitary adenomas.
    Cristina C; Perez-Millan MI; Luque G; Dulce RA; Sevlever G; Berner SI; Becu-Villalobos D
    Endocr Pathol; 2010 Sep; 21(3):154-60. PubMed ID: 20473646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules.
    Viacava P; Bocci G; Tonacchera M; Fanelli G; DeServi M; Agretti P; Berti E; Goletti O; Aretini P; Resta ML; Bevilacqua G; Naccarato AG
    Thyroid; 2007 Mar; 17(3):191-7. PubMed ID: 17381350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome.
    Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
    J Endocrinol; 2000 May; 165(2):475-81. PubMed ID: 10810311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.
    Korsisaari N; Ross J; Wu X; Kowanetz M; Pal N; Hall L; Eastham-Anderson J; Forrest WF; Van Bruggen N; Peale FV; Ferrara N
    Clin Cancer Res; 2008 Jan; 14(1):249-58. PubMed ID: 18172277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas.
    Corlan AS; Cîmpean AM; Melnic E; Raica M; Sarb S
    Eur J Histochem; 2019 Mar; 63(1):. PubMed ID: 30838843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
    Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
    J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.
    Hunter JA; Skelly RH; Aylwin SJ; Geddes JF; Evanson J; Besser GM; Monson JP; Burrin JM
    Eur J Endocrinol; 2003 Feb; 148(2):203-11. PubMed ID: 12590639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment.
    Kurosaki M; Saegert W; Abe T; Lüdecke DK
    Neurol Res; 2008 Jun; 30(5):518-22. PubMed ID: 18953743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
    Joo YE; Rew JS; Seo YH; Choi SK; Kim YJ; Park CS; Kim SJ
    J Clin Gastroenterol; 2003 Jul; 37(1):28-33. PubMed ID: 12811205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.
    da Rocha AA; Giorgi RR; de Sa SV; Correa-Giannella ML; Fortes MA; Cavaleiro AM; Machado MC; Cescato VA; Bronstein MD; Giannella-Neto D
    Pituitary; 2006; 9(2):83-92. PubMed ID: 16832584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma.
    Ma J; Zhang L; Ru GQ; Zhao ZS; Xu WJ
    World J Gastroenterol; 2007 Mar; 13(11):1680-6. PubMed ID: 17461470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas.
    Jameson JL; Klibanski A; Black PM; Zervas NT; Lindell CM; Hsu DW; Ridgway EC; Habener JF
    J Clin Invest; 1987 Nov; 80(5):1472-8. PubMed ID: 2824561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocarcinoma].
    Jiang CQ; Liu ZS; Qian Q; He YM; Yuan YF; Ai ZL
    Ai Zheng; 2003 Nov; 22(11):1170-4. PubMed ID: 14613646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis in pituitary adenomas and the normal pituitary gland.
    Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1159-62. PubMed ID: 10720055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.